N. Rifai et al., USE OF A RAPID HPLC ASSAY FOR DETERMINATION OF PHARMACOKINETIC PARAMETERS OF IBUPROFEN IN PATIENTS WITH CYSTIC-FIBROSIS, Clinical chemistry, 42(11), 1996, pp. 1812-1816
High doses of ibuprofen have been shown to delay the progression of lu
ng disease without serious adverse effects in patients with cystic fib
rosis. To be effective, peak ibuprofen concentration of 50 to 100 mg/L
has to be achieved. We developed an HPLC assay to rapidly determine p
lasma ibuprofen concentration. We used this assay to determine the pha
rmacokinetics of ibuprofen in patients with cystic fibrosis. The assay
possessed Linearity up to 500 mg/L, sensitivity to 1 mg/L, average re
covery of 98%, and run-to-run precision (n = 23) of 3%. Furthermore, t
he assay proved to be free of interference from 51 medications. Observ
ed time to peak concentration varied significantly between those recei
ving ibuprofen tablets (mean + SD, 94 +/- 29 min, n = 16) and syrup (3
0 +/- 0 min, n = 4) (P <0.0001). We conclude that the method described
here is ideal, for therapeutic monitoring of ibuprofen.